Temporal pattern and costs of rehospitalization in atrial fibrillation/atrial flutter patients with one or more additional risk factors

Journal of Medical Economics

Volumn 15, Issue 3, 2012, Pages 548-555

  Amin, Alpesh N ^a   Jhaveri, Mehul ^b   Lin, Jay ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SANOFI   (France)

^c Novosys Health   (United States)

Author keywords

Atrial fibrillation; Cardiovascular disease; Cost; Hospitalization; Patient readmission; Risk factors

Indexed keywords

ACUTE HEART INFARCTION; AGED; ANGINA PECTORIS; ARTICLE; BLEEDING; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; CORONARY ARTERY ATHEROSCLEROSIS; DATA BASE; FEMALE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART VENTRICLE ARRHYTHMIA; HOSPITAL COST; HOSPITAL READMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; RISK FACTOR; STROKE; TRANSIENT ISCHEMIC ATTACK; UNITED STATES; VENOUS THROMBOEMBOLISM;

AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; ATRIAL FLUTTER; COHORT STUDIES; FEMALE; HEALTH RESOURCES; HUMANS; MALE; PATIENT READMISSION; RETROSPECTIVE STUDIES; RISK FACTORS; UNITED STATES;

EID: 84859176923     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2012.664224     Document Type: Article

References (20)

1. Naccarelli GV, Varker H, Lin J, et al. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol 2009;104:1534-9
2. Kannel WB, Wolf PA, Benjamin EJ, et al. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: Population-based estimates. Am J Cardiol 1998;82:2N-9N
3. Stewart S, Hart CL, Hole DJ, et al. A population-based study of the long-Term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med 2002;113:359-64
4. Reynolds MR, Essebag V, Zimetbaum P, et al. Healthcare resource utilization and costs associated with recurrent episodes of atrial fibrillation: The FRACTAL registry. J Cardiovasc Electrophysiol 2007;18:628-33
5. Kim MH, Lin J, Hussein M, et al. Incidence and temporal pattern of hospital readmissions for patients with atrial fibrillation. Curr Med Res Opin 2009; 25:1215-20
6. Kim MH, Lin J, Hussein M, et al. Cost of atrial fibrillation in United States managed care organizations. Adv Ther 2009;26:847-57
7. Naccarelli GV, Johnston SS, Lin J, et al. Cost burden of cardiovascular hospitalization and mortality in ATHENA-like patients with atrial fibrillation/atrial flutter in the United States. Clin Cardiol 2010;33:270-9
8. Kim MH, Johnston SS, Chu B-C, et al. Estimation of total incremental health care cost in patients with atrial fibrillation in the United States. Circ Cardiovasc Qual Outcomes 2011;4:313-20
9. Hohnloser SH, Crijns HJ, van Eickels M, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009;360:668-78
10. Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the Medicare fee-for-service program. N Engl J Med 2009;360:1418-28
11. Medicare Payment Advisory Commission. Report to Congress: Promoting greater efficiency in medicare. Washington, DC: 2007. http://www.medpac. gov/documents/jun07-entirereport.pdf. Accessed October 10, 2011
12. Spyropoulos AC, Hussein M, Lin J, et al. Rates of symptomatic venous thromboembolism in US surgical patients: A retrospective administrative database study. J Thromb Thrombolysis 2009;28:458-64
13. Prescott JD, Factor S, Pill M, et al. Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database. J Manag Care Pharm 2007;13:44-52
14. Gore M, Sadosky A, Zlateva G, et al. Initial use of pregabalin, patterns of painrelated pharmacotherapy, and healthcare resource use among older patients with fibromyalgia. Am J Manag Care 2010;16:S144-53
15. Lang K, Sussman M, Friedman M, et al. Incidence and costs of treatmentrelated complications among patients with advanced squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 2009; 135:582-8
16. Kim MH, Klingman D, Lin J, et al. Patterns and predictors of discontinuation of rhythm-control drug therapy in patients with newly diagnosed atrial fibrillation. Pharmacotherapy 2009;29:1417-26
17. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987;40:373-83
18. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: Results from the National Registry of Atrial Fibrillation. JAMA 2001;285:2864-70
19. Hughes M, Lip GY. Stroke and thromboembolism in atrial fibrillation: A systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb Haemost 2008;99:295-304
20. Hohnloser SH, Connolly SJ, Crijns HJ, et al. Rationale and design of ATHENA: A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patiENts with Atrial fibrillation/atrial flutter. J Cardiovasc Electrophysiol 2008; 19:69-73